Incyte Corporation

This study offers continued access to the drug parsaclisib for people with B-cell cancers who were already benefiting from it in earlier trials. About 112 participants will keep taking the same dose, either alone or with other drugs, to monitor long-term safety and tolerability. …

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This Phase 2 trial tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 130 participants aged 12 and older will …

This early-stage trial tests an experimental drug called INCB000928, given alone or with the standard drug ruxolitinib, for people with myelofibrosis who have severe anemia or need regular blood transfusions. The main goals are to check the drug's safety, find the right dose, and…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This phase 3 trial tests an oral drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and bumpy skin lesions. Participants receive either the drug or a placebo for 24 weeks. The study measures whether the drug reduces itch severity an…

This early-stage trial tests an experimental drug called INCB057643, given alone or with the standard drug ruxolitinib, in about 140 adults with myelofibrosis or other advanced blood cancers. The main goal is to check safety and side effects, while also measuring if the drug can …

This study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk disease will take part. The goal is to see if the new combination keeps can…

This study tests a new drug called axatilimab against the best current treatments for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must be at least 12 years old and have tried at least two prior treatments withou…

This phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The go…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…

This study tests a new drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The main goals are to see if the drug shrinks tumors and to check its safety. Participants take the drug and are monitored for side e…

This study tests a modified intravenous dosing schedule of tafasitamab combined with oral lenalidomide in 53 adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for a stem cell transplant. The main goal is to evaluate safety and how the drug move…

This Phase 3 trial tests whether adding tafasitamab to lenalidomide and rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer worsening. About 654 participants receive either the three-drug combo or lenalidomide plus rituximab …

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …

This phase 3 trial tests an oral drug called povorcitinib in 349 adults with prurigo nodularis, a condition causing intense itching and hard skin bumps. Participants receive either the drug or a placebo for 24 weeks. The goal is to see if the drug reduces itch and clears skin les…

This early-stage study is testing a new drug, INCA033989, in 72 healthy adults aged 18 to 55. The goal is to see how the drug moves through the body and whether it is safe when given as a shot under the skin or through an IV. No disease is being treated — this is a first step to …